Comparative effectiveness, safety and persistence of ocrelizumab versus natalizumab in multiple sclerosis: A real-world, multi-center, propensity score-matched study.

Neurotherapeutics · 2025 · PMC12014400 · PMID 39880749

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

only marginally significantno p-value reported

Notably, the only recent study with a 5-year follow-up which compared OCR-treated patients in OPERA I and II with different DMTs in a real-world cohort, found that OCR reduced the risk of relapse by 46 % compared to NTZ, though its effect on disability accumulation was only marginally significant (p = 0.048) [ 25 ].

also in 5,076 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.